UAE establishes itself as a clinical diagnostics leader amid regional advancement
Investment in genomics, laboratory networks and artificial intelligence is positioning the Emirates at the forefront of diagnostic innovation, translating scientific breakthroughs into transformative patient care across the region.
The UAE is establishing itself as one of the most advanced clinical diagnostics markets in the Middle East, driven by a strategic convergence of technological investment, infrastructure development and regulatory support that together create a model for healthcare systems seeking to accelerate innovation at scale.
This emergence reflects more than the deployment of sophisticated technologies alone. Rather, the Emirates is building the comprehensive capabilities required to translate scientific advancement into routine clinical practice. By developing genomic infrastructure, laboratory networks, artificial intelligence-enabled diagnostics and reimbursement frameworks in parallel, the country is creating a holistic ecosystem where innovation becomes measurable clinical benefit.
The global clinical diagnostics market is forecast to expand from US$115.7 billion in 2026 to US$152.1 billion by 2031, representing compound annual growth of 5.5 per cent. Within this landscape, the Middle East market stands at approximately US$5.4 billion in 2026, with the UAE building particular strength in molecular diagnostics, decentralised testing and artificial intelligence-powered pathology.
Genomic medicine exemplifies this progress. The Emirati Genome Programme is constructing population-level genomic datasets to enable personalised healthcare and research, whilst Cleveland Clinic Abu Dhabi provides precision oncology services, next-generation sequencing, genetic counselling and hereditary cancer testing. Since January 2025, genetic testing has become part of mandatory premarital screening for Emiratis, covering 570 genes associated with more than 840 genetic conditions, embedding precision medicine into preventive healthcare.
Laboratory infrastructure, too, has undergone significant expansion. PureHealth’s PureLab, the UAE’s largest integrated laboratory network, conducted 34 million tests in 2025, representing 17 per cent growth from 29 million tests in 2024. This expansion reflects a broader shift in diagnostics: the combination of centralised laboratory capacity with decentralised testing closer to patients, a transition that is reshaping how diagnostic services reach communities.
Point-of-care testing, which brings rapid diagnostic platforms into urgent care, community and primary care settings beyond traditional laboratories, is forecast to grow from US$19.1 billion globally in 2026 to US$26.2 billion by 2031, growing at 6.4 per cent annually. The molecular diagnostics segment specifically is projected to expand from US$26.9 billion in 2026 to US$36 billion by 2031, driven by oncology molecular profiling, companion diagnostics and infectious disease surveillance.
Reimbursement frameworks have expanded to support this evolution. The UAE now covers oncology next-generation sequencing and companion diagnostics, enabling healthcare systems to deploy these technologies within sustainable financial models. Simultaneously, how diagnostic technologies are procured is shifting. Large hospital groups and integrated primary care networks are becoming increasingly central customers, with connectivity, remote quality monitoring and laboratory information system integration now baseline requirements in regional tenders.
These developments will be examined in greater detail at World Health Expo 2027, opening in Dubai on 25 January. The event is expected to welcome more than 90,000 attendees, 4,200 exhibitors and representatives from over 195 countries, with sessions devoted to how healthcare systems can harness diagnostic innovation to strengthen clinical decision-making and drive measurable patient outcomes across the region.
Source: WAM